Triple-negative breast cancer does not respond to targeted breast cancer treatments, which limits treatment to primarily chemotherapy for now.

March 28, 2007 — A new study clearly reveals the survival disadvantage for the so-called "triple-negative" subtype of breast cancer compared with other types of breast cancer. These tumors test ...

Datroway significantly improves overall and progression-free survival in metastatic triple-negative breast cancer patients ineligible for immunotherapy. TROPION-Breast02 trial results highlight ...

A new study has found that a commonly prescribed anti-nausea medication is associated with a better prognosis for women with early-stage breast cancer, particularly triple-negative breast cancer. The ...

Sacituzumab govitecan targets Trop-2 and delivers potent chemo directly to TNBC cells. PARP inhibitors are effective in TNBC patients with BRCA mutations. Immune checkpoint inhibitors benefit patients ...

Patient-derived xenografts (PDX) may accurately predict early recurrence and survival outcomes in triple negative breast cancer (TNBC), offering a potential tool for tailoring treatment strategies to ...

PD-1 inhibition before and after surgery for high-risk early triple-negative breast cancer (TNBC) led to significant improvement in overall survival (OS), according to updated results from a large ...

An international team led by a UK investigator finds that the immunotherapy drug pembrolizumab when given with chemotherapy for early-stage triple-negative breast cancer (TNBC) in the randomised ...